Since enhanced platelet activation and secretion—especially in hypercholesterolemia—is well documented in patients with CAD, we hypothesized that platelets contribute to PCSK9 activity and thus the regulation of LDL plasma levels. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.